Overview

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Status:
Completed
Trial end date:
2016-06-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and gastroparesis. Study drug (relamorelin and placebo) will be administered subcutaneously in a blinded fashion.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Motus Therapeutics, Inc.